Abbott Laboratories Management Discusses Q1 2012 Results - Earnings Call ... Seeking Alpha Daclizumab is a next-generation biologic in development for MS. Last year, Abbott and our partner company announced promising results from the first of 2 registrational studies. The first -- the Phase III study called DECIDE is ongoing. |
